HDAC1 overexpression conferred resistance to BTZ in MM cells, and administration of the HDACi romidepsin restored sensitivity to BTZ in HDAC1-overexpressing cells both in vitro and in vivo20. The gene discussed is HDAC1; the disease is Miyoshi myopathy.